Miscellaneous Ocular Agents

Corneal Abnormalities Seen With Down Syndrome

June 25, 2018

There were differences in steepest keratometry of 47.35 diopters in patients with DS vs 43.7 diopters in control subjects. There were also differences in corneal pachymetry of 503µm in patients with DS versus 545µm in controls.

Amblyopia, Strabismus May Slow Test Performance in Children

June 15, 2018

Compared with children in the control group, children with amblyopia had a slower mean time to completion (P=.001), as did children with non-amblyopic strabismus (P=.002).

Treatment for Limbal Stem Cell Deficiency Gets Orphan Drug Designation

By June 12, 2018

GPLSCD01 is an investigational treatment made up of ex vivo expanded autologous human corneal epithelial cells containing stem cells.

Time Spent in Education Is Causal Risk Factor for Myopia

June 07, 2018

A U.K. university graduate with 17 years of education would be at least −1 dioptre more myopic, on average, than someone who left school at age 16 with 12 years of education.

First Artificial Iris FDA-Approved for Aniridia, Other Iris Defects

By May 31, 2018

In a clinical trial of 389 individuals with iris defects, 70% of patients reported a significant decrease in light sensitivity and glare.

Uveal Effusion Reported After Initiation of Anti-PD-1, -PD-L1

May 11, 2018

The patients were 2 white men aged 52 and 85 years with metastatic cutaneous melanoma and a 68-year-old African-American man with metastatic adenocarcinoma of the lung. All 3 patients were receiving anti-PD-1 and anti-PD-L1 monoclonal antibody therapy.

Eyes of Ebola Survivors Show Localized Pathological Changes

May 07, 2018

All lesions respected the horizontal raphe, and the fovea was spared. A V-shaped hyperreflectivity of the outer nuclear layer was seen with OCT imaging, overlying discontinuities of the ellipsoid zone and interdigitation zone in smaller lesions.

Rhopressa Now Available for Open-Angle Glaucoma, Ocular Hypertension

By April 30, 2018

The approval was based on results from 3 randomized trials which found that Rhopressa was associated with a reduction in intraocular pressure of up to 5mmHg.

FDA Fast Tracks Gene Therapy for X-Linked Retinitis Pigmentosa

By April 27, 2018

XLRP represents the most severe form of retinitis pigmentosa (RP), an inherited retinal disease characterized by progressive retinal degeneration and vision loss that ends in complete blindness.

Dark Chocolate Can Improve Contrast Sensitivity, Visual Acuity

April 27, 2018

Visual acuity improved slightly more after consumption of dark vs milk chocolate.

One-Hour Plasma Glucose Useful Predictor of Diabetic Retinopathy

April 16, 2018

The researchers found that the prevalence and incidence of DR changed in a similar manner across the distributions of 1h-PG and 2h-PG concentrations.

FDA Approves Unique Device for Diabetic Retinopathy Screening

By April 11, 2018

This is the first device authorized for marketing that provides a screening decision without the need for clinician interpretation.

Contact Lenses With Light-Adaptive Technology Get FDA Approval

By April 11, 2018

The contact lenses contain a photochromic additive that adapts the amount of visible light filtered to the eye based on the amount of UV light to which they are exposed.

Composite Subretinal Implants May Lessen Vision Loss From AMD

April 05, 2018

A composite implant which consists of a polarized monolayer of human embryonic stem cell-derived RPE on an ultrathin parylene substrate, may improve visual function in some patients.

Vitamin A Appears Helpful in Pediatric Retinitis Pigmentosa

April 02, 2018

The researchers found that in the unadjusted model, the estimated mean rates of change were −0.0713 loge unit/year for the vitamin A cohort and −0.1419 loge unit per year for the control cohort.

Early Age-Related Macular Degeneration Linked to High HDL

March 30, 2018

The researchers found that the incidence rates of early and advanced AMD were 79.9 and 18.6 per 1,000 person-years, respectively, corresponding to five-years risks of 32.9 and 8.9%.

Intravitreal Anti-VEGF Use Not Tied to Systemic Adverse Events

March 26, 2018

In the most recent and exhaustive reviews, bevacizumab was not associated with an increase in the risk of systemic adverse events compared with ranibizumab. In patients with age-related macular degeneration, ranibizumab may be associated with increased risk of nonocular hemorrhage compared with control treatments.

Additional Strength of Lucentis Prefilled Syringe FDA-Approved

By March 21, 2018

The 0.3mg PFS marks the first approved syringe with an anti-vascular endothelial growth factor (VEGF) to treat all forms of diabetic retinopathy with or without diabetic macular edema (DME).

Eylea Meets Endpoint in Non-Proliferative Diabetic Retinopathy Trial

By March 19, 2018

Results so far (at week 24) show more than half of patients who received Eylea experienced a 2-step or greater improvement from baseline on the DRSS vs. patients who received a sham injection (58% vs 6%; P<0.0001).

Prevalence of Persistent DME Evaluated After Anti-VEGF Therapy

February 02, 2018

Persistent diabetic macular edema more likely with bevacizumab than aflibercept or ranibizumab

Diet Soda Independently Linked to Higher Diabetic Retinopathy Risk

January 30, 2018

Compared to those with no diet soft drink consumption, there was an independent association between high diet soft drink consumption and increased likelihood of having PDR (odds ratio, 2.51).

Growth hormone releasing hormone (GHRH) agonists protect against diabetic retinopathy in animal model

January 19, 2018

GHRH and GHRH receptor levels are decreased in diabetic rats and humans.

Noninvasive Marker May ID Severity of Diabetic Retinopathy

January 18, 2018

"Further longitudinal studies seem warranted to determine whether DRIL is a clinically relevant noninvasive morphological marker in eyes with DME," the authors write.

NDA Submitted for Durasert 3-Year Implant for Posterior Segment Uveitis

By January 08, 2018

The NDA submission was supported by data from two Phase 3 studies that met the primary efficacy endpoint of prevention of recurrence of uveitis at 6 months of follow-up (P<0.001).

FDA to Review New Treatment for Post-Op Ocular Pain, Inflammation

By January 08, 2018

If approved Inveltys would become the first twice-daily post-surgical topical treatment; all current treatments are approved for four-times-a-day dosing.

Luxturna Approved to Treat Inherited Form of Vision Loss

By December 19, 2017

Luxturna is the first directly administered gene therapy approved in the U.S. that targets a disease caused by mutations in a specific gene.

Novel Once-Daily Eye Drop Approved for Lowering Elevated IOP in Glaucoma

By December 19, 2017

Rhopressa (netarsudil ophthalmic solution) 0.02% is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Treatment for Leber's Hereditary Optic Neuropathy Gains Fast Track Status

By December 18, 2017

Elamipretide has also been granted Fast Track designation for treating primary mitochondrial myopathy (PMM) - which gained Orphan Drug Designation in September - and Barth syndrome

Intraocular Hemorrhage Occurrence for Novel vs. Traditional Antithrombotic Agents

December 14, 2017

The researchers found that the risk of developing an intraocular hemorrhage was reduced with dabigatran or rivaroxaban at 365 days (hazard ratio, 0.75; 95% confidence interval, 0.58 to 0.97; P=0.03) but not at 90 days (hazard ratio, 0.73; 95% confidence interval, 0.22 to 2.63; P=0.13).

Omidria Approved for Use in Pediatric Patients

By December 12, 2017

FDA gave approval following review of efficacy and safety data from a pediatric clinical trial.